Knights of Columbus Asset Advisors LLC Invests $595,000 in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Knights of Columbus Asset Advisors LLC invested approximately $595,000 to acquire 32,833 shares of NewAmsterdam Pharma Company N.V. during the 2nd quarter.
• Analysts have set a consensus target price of $42.00 for NewAmsterdam Pharma, with the stock currently rated as a "Moderate Buy" by eight analysts.
• The company's latest earnings report showed a revenue of $19.15 million for the quarter, significantly surpassing analyst estimates of $1.44 million.

Knights of Columbus Asset Advisors LLC purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,833 shares of the company's stock, valued at approximately $595,000.

Several other hedge funds have also made changes to their positions in NAMS. California State Teachers Retirement System lifted its position in shares of NewAmsterdam Pharma by 23.5% during the fourth quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock worth $499,000 after purchasing an additional 3,694 shares in the last quarter. Avanza Fonder AB acquired a new stake in NewAmsterdam Pharma in the 1st quarter valued at about $127,000. Handelsbanken Fonder AB raised its position in NewAmsterdam Pharma by 38.7% in the 1st quarter. Handelsbanken Fonder AB now owns 260,000 shares of the company's stock valued at $5,322,000 after purchasing an additional 72,596 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares in the last quarter. Finally, Lisanti Capital Growth LLC raised its position in NewAmsterdam Pharma by 26.9% in the 1st quarter. Lisanti Capital Growth LLC now owns 49,110 shares of the company's stock valued at $1,005,000 after purchasing an additional 10,395 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on NAMS. Citigroup began coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price target on the stock. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target on the stock. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Wells Fargo & Company initiated coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They issued an "overweight" rating and a $45.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $42.00.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS opened at $32.21 on Wednesday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $34.62. The firm has a market capitalization of $3.63 billion, a PE ratio of -19.88 and a beta of 0.02. The stock's 50-day simple moving average is $25.62 and its 200-day simple moving average is $21.40.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The business had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper purchased 1,260 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were purchased at an average price of $24.99 per share, for a total transaction of $31,487.40. Following the purchase, the director directly owned 3,027,864 shares of the company's stock, valued at $75,666,321.36. This represents a 0.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the firm's stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider owned 119,302 shares in the company, valued at $2,897,845.58. This represents a 29.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 2,391 shares of company stock worth $58,424 and have sold 324,954 shares worth $7,844,906. 20.84% of the stock is owned by insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.